Clinical Trial Update: Effect of Pitavastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease [Phase 4]

View source ↗

Summary

A Phase 4 trial assessing the impact of pitavastatin on erythrocyte membrane fatty acid composition in patients with chronic kidney disease has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• Pitavastatin (Pitavastatin)

Snippet

Sponsor: Dong-A University | Conditions: Chronic Kidney Disease | Phase 4 | Status: COMPLETED